<?xml version='1.0' encoding='utf-8'?>
<document id="31887668"><sentence text="Metabolic proï¬ling of tyrosine kinase inhibitor nintedanib using metabolomics."><entity charOffset="22-30" id="DDI-PubMed.31887668.s1.e0" text="tyrosine" /><entity charOffset="48-58" id="DDI-PubMed.31887668.s1.e1" text="nintedanib" /><pair ddi="false" e1="DDI-PubMed.31887668.s1.e0" e2="DDI-PubMed.31887668.s1.e0" /><pair ddi="false" e1="DDI-PubMed.31887668.s1.e0" e2="DDI-PubMed.31887668.s1.e1" /></sentence><sentence text="Nintedanib is a promising tyrosine kinase inhibitor for clinically treating idiopathic pulmonary fibrosis (IPF)"><entity charOffset="0-10" id="DDI-PubMed.31887668.s2.e0" text="Nintedanib" /><entity charOffset="26-34" id="DDI-PubMed.31887668.s2.e1" text="tyrosine" /><pair ddi="false" e1="DDI-PubMed.31887668.s2.e0" e2="DDI-PubMed.31887668.s2.e0" /><pair ddi="false" e1="DDI-PubMed.31887668.s2.e0" e2="DDI-PubMed.31887668.s2.e1" /></sentence><sentence text=" Some clinical cases reported that nintedanib treatment can cause hepatotoxicity and myocardial toxicity"><entity charOffset="35-45" id="DDI-PubMed.31887668.s3.e0" text="nintedanib" /></sentence><sentence text=" U" /><sentence text=" S" /><sentence text=" FDA warns the potential drug-drug interaction when it is co-administrated with other drugs" /><sentence text=" In order to understand the potential toxicity of nintedanib and avoid drug-drug interaction, the metabolism of nintedanib was systematically investigated in human liver microsomes and mice using metabolomics approach, and the toxicity of metabolites was predicted by ADMET lab"><entity charOffset="50-60" id="DDI-PubMed.31887668.s7.e0" text="nintedanib" /><entity charOffset="112-122" id="DDI-PubMed.31887668.s7.e1" text="nintedanib" /><pair ddi="false" e1="DDI-PubMed.31887668.s7.e0" e2="DDI-PubMed.31887668.s7.e0" /><pair ddi="false" e1="DDI-PubMed.31887668.s7.e0" e2="DDI-PubMed.31887668.s7.e1" /></sentence><sentence text=" Nineteen metabolites were detected in vivo and in vitro metabolism, and 8 of them were undescribed" /><sentence text=" Calculated partition coefficients (Clog P) were used to distinguish the isomers of nintedanib metabolites in this study"><entity charOffset="84-94" id="DDI-PubMed.31887668.s9.e0" text="nintedanib" /></sentence><sentence text=" The major metabolic pathways of nintedanib majorly included hydroxylation, demethylation, glucuronidation, and acetylation reactions"><entity charOffset="33-43" id="DDI-PubMed.31887668.s10.e0" text="nintedanib" /></sentence><sentence text=" The ADMET prediction indicated that nintedanib was a substrate of the cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp)"><entity charOffset="37-47" id="DDI-PubMed.31887668.s11.e0" text="nintedanib" /></sentence><sentence text=" And nintedanib and most of its metabolites might possess potential hepatotoxicity and cardiotoxicity"><entity charOffset="5-15" id="DDI-PubMed.31887668.s12.e0" text="nintedanib" /></sentence><sentence text=" This study provided a global view of nintedanib metabolism, which could be used to understand the mechanism of adverse effects related to nintedanib and its potential drug-drug interaction"><entity charOffset="38-48" id="DDI-PubMed.31887668.s13.e0" text="nintedanib" /><entity charOffset="139-149" id="DDI-PubMed.31887668.s13.e1" text="nintedanib" /><pair ddi="false" e1="DDI-PubMed.31887668.s13.e0" e2="DDI-PubMed.31887668.s13.e0" /><pair ddi="true" e1="DDI-PubMed.31887668.s13.e0" e2="DDI-PubMed.31887668.s13.e1" /></sentence><sentence text="" /></document>